2011 Annual Meeting & Banquet at the AUA
Saturday, May 14, 2011
Grand Hyatt Washington
Washington, DC
7:55 a.m. – 8:00 a.m.  
Introduction and Welcome  
Zhou Wang, PhD  
University of Pittsburgh  
Eric Klein, MD  
Cleveland Clinic Foundation  
Brent Hollenbeck, MD  
University of Michigan Health System  

I. CASTRATION RESISTANT PROSTATE CANCER  
Moderator: Eric Klein, MD  
8:00 a.m. – 8:20 a.m.  
Taxane Chemotherapy Targets Androgen Receptor Activity and Transport in Prostate Cancer  
Natasha Kyprianou, MD, PhD  
University of Kentucky  

8:20 a.m. – 8:25 a.m.  
Questions & Discussion  

8:25 a.m. – 8:45 a.m.  
Targeting Cell Migration: Novel Biomarkers and Therapeutic Targets for Metastasis  
John Lewis, PhD  
London Regional Cancer Program  

8:45 a.m. – 8:50 a.m.  
Questions & Discussion  

8:50 a.m. – 9:10 a.m.  
Targeting Stress-Induced Cytoprotective Chaperones, CLU and Hsp27, in CRPC  
Martin Gleave, MD  
Vancouver Prostate Center  

9:10 a.m. – 9:15 a.m.  
Questions & Discussion  

II. CHEMOTHERAPY RESISTANT CANCER  
Moderator: Brent Hollenbeck, MD  
9:15 a.m. – 9:35 a.m.  
The Multiple Faces of HOX Gene Function in Breast Cancer  
Sara Sukumar, PhD  
Johns Hopkins University School of Medicine  

9:35 a.m. – 9:40 a.m.  
Questions & Discussion  

9:40 a.m. – 10:00 a.m.  
Mechanisms of Resistance to Pro-Apoptotic Therapies  
Aria F. Oloomi, MD  
Massachusetts General Hospital  

10:00 a.m. – 10:05 a.m.  
Questions & Discussion  

10:05 a.m. – 10:25 a.m.  
Translating Metastasis Biology into Cancer Therapy  
Dan Theodorescu, MD, PhD  
University of Colorado  

10:25 a.m. – 10:30 a.m.  
Questions & Discussion  

III. THE COFFEY LECTURESHP  
Moderator: Zhou Wang, PhD  
10:30 a.m. – 11:25 a.m.  
Next Generation Antiandrogen Therapy  
Charles L. Sawyers, MD  
Memorial Sloan-Kettering Cancer Center; Howard Hughes Medical Institute  

11:25 a.m. – 12:25 p.m.  
SUO Annual Business Luncheon Meeting  
(Members Only)  
Location: Independence BCDE  

AFTERNOON SESSION  
12:30 p.m. – 5:00 p.m.  
Grand Hyatt Washington  

12:30 p.m. – 12:45 p.m.  
Welcome and Introductions  
Eric Klein, MD  
Cleveland Clinic  

Presentation of Prostate Cancer Foundation Award  
Stuart Holden, MD  
Prostate Cancer Foundation  

Program Overview  
Brent Hollenbeck, MD  
University of Michigan
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
</table>
| 12:45 p.m. – 1:15 p.m. | Whitmore Lecture: Outcomes Research and the Translational Population Sciences  
Mark Litwin, MD  
University of California Los Angeles |                                    |
| PROSTATE CANCER I | 1:15 p.m. – 1:30 p.m. Natural History of Prostate Cancer and Its Implications for Over- and Under-Treatment  
Peter Albertsen, MD  
University of Connecticut Health Center |                                    |
|                  | 1:30 p.m. – 1:45 p.m. Improving the Value of PSA  
Peter Carroll, MD  
University of California San Francisco |                                    |
|                  | 1:45 p.m. – 1:55 p.m. Grassroots Collaborations to Improve Quality in Urologic Oncology  
David Miller, MD, MPH  
University of Michigan |                                    |
| KIDNEY CANCER    | 1:55 p.m. – 2:05 p.m. Update on Targeted Therapies for Advanced Cancer  
Allan Pantuck, MD  
University of California Los Angeles |                                    |
|                  | 2:05 p.m. – 2:15 p.m. A Practical Approach to Managing Patients With Kidney Tumors  
Robert Uzzo, MD  
Fox Chase Cancer Center |                                    |
|                  | 2:15 p.m. – 2:30 p.m. Underuse of Partial Nephrectomy for Kidney Cancer and Its Downstream Consequences  
William Huang, MD  
NYU Urology Associates |                                    |
|                  | 2:30 p.m. – 2:55 p.m. Case Management Panel: Approaches to the Small Renal Mass  
Observation: Michael Jewett, MD (Moderator)  
Princess Margaret Hospital, Toronto  
Ablation: Jeff Cadeddu, MD  
UT Southwestern  
Surgery: Paul Russo, MD  
Memorial Sloan-Kettering Cancer Center |                                    |
| TESTIS CANCER    | 2:55 p.m. – 3:05 p.m. Testis Cancer Surveillance and Implications for Observation Protocols  
Christopher Saigal, MD  
University of California Los Angeles / RAND |                                    |
|                  | 3:05 p.m. – 3:20 p.m. Debate: Laparoscopic vs. Open RPLND  
Open: Richard Foster, MD  
Indiana University Medical Center  
Lap: Sam Bhayani, MD  
Washington University School of Medicine |                                    |
|                  | 3:20 p.m. – 3:45 p.m. Case Management Panel  
Moderator: Joel Sheinfeld, MD  
Memorial Sloan-Kettering Cancer Center |                                    |
| PROSTATE CANCER II| 3:45 p.m. – 3:55 p.m. Patient Reported Outcomes: A Web-Based Strategy for Gauging Progress  
Andrew Vickers, PhD  
Memorial Sloan-Kettering Cancer Center |                                    |
|                  | 3:55 p.m. – 4:05 p.m. Updates on Novel Therapies for Advanced Prostate Cancer  
Martin Gleave, MD  
The Prostate Centre at VGH |                                    |
|                  | 4:05 p.m. – 4:35 p.m. Case Management Panel: Adjuvant vs. Salvage Radiation Role of Decision  
Analysis: Sean Elliott, MD (Moderator)  
University of Minnesota  
Adjuvant: Ian Thompson, MD  
University of Texas Health Science Center  
Salvage: Andrew Stephenson, MD  
Cleveland Clinic Foundation |                                    |
| BLADDER CANCER   | 4:35 p.m. – 4:50 p.m. Improving the Quality of Bladder Cancer Care: Personalizing Care Through Molecular-Based Research  
Colin Dinney, MD  
MD Anderson Cancer Center |                                    |
|                  | 4:50 p.m. – 5:00 p.m. Use and Effectiveness of Interventions for Invasive Bladder Cancer  
John Gore, MD  
University of Washington |                                    |
|                  | 6:30 p.m. – 10:00 p.m. SUO Reception and Dinner  
(Pre-Registration Required)  
Location: Independence BCDE & Corridor A |                                    |

**FRIDAY, MAY 13, 2011**  
SUO Board of Directors Dinner & Board Meeting  
Grand Hyatt Washington • McPherson Square  
5:00 p.m. – 10:00 p.m.

**SATURDAY, MAY 14, 2011**  
SUO/SBUR Joint Meeting (Morning Program)  
Grand Hyatt Washington • Independence A  
8:00 a.m. – 11:25 a.m.

**SUO Business Meeting (Members Only)**  
Grand Hyatt Washington • Independence BCDE  
11:25 a.m. – 12:25 p.m.

**SUO Annual Meeting (Afternoon Program)**  
Grand Hyatt Washington • Independence A  
12:30 p.m. – 5:00 p.m.

**SUO Reception and Dinner**  
Grand Hyatt Washington • Independence BCDE & Corridor A  
6:30 p.m. – 10:00 p.m.

**MondAy, May 16, 2011**  
SUO-CTC Board of Directors Meeting  
(For CTC Board and CTC Committees Only)  
Grand Hyatt Washington • Lafayette  
10:00 a.m. – 12:00 p.m.
CME ACCREDITATION

SUO/SBUR Educational Needs (Morning)
Resistance of urologic cancers to existing therapies is a major challenge for physicians and basic researchers. Physicians need a better understanding of current research progresses on therapy resistance of urologic cancers. This session will focus on mechanisms leading to the therapy resistance and potential new approaches to overcome the resistance. Participants will learn about the current research directions related to the therapy resistance and how the new findings are being translated into therapies for patients with urologic cancers.

SUO/SBUR Educational Objectives (Morning)
1. Review foundational knowledge in the areas of therapy resistance of various urologic cancers.
2. Identify practical applications of basic research findings towards the treatment of therapy resistant urologic cancers.
3. Identify new research directions to overcome therapy resistance of a wide range of urologic malignancies.

SUO Educational Needs (Afternoon)
There is a need for urologic oncologists to better understand the challenges facing the healthcare system, particularly the growing quality gap. Further, with reforms looming, clinicians should understand the basics behind quality measurement and improvement and policies that will ultimately affect clinical practice.

Bladder cancer is the second most common genitourinary cancer in males and the fourth most common in females. There will be an estimated 71,000 new cases and 15,000 deaths from bladder cancer in 2010. Approximately 70% of the time, patients present with non-muscle invasive disease. Of those, 70% are Ta lesions, 20% T1, and 10% carcinoma in situ (CIS). Muscle invasive cancer accounts for the remainder of patients and 80% of these patients present de novo with invasive cancer as their first manifestation of the disease. Level 1 evidence regarding the optimal treatment strategies for bladder cancer is lacking. Given the widely disparate outcomes across providers and hospitals,

Radical cystectomy is considered the standard of care for treatment of muscle invasive urothelial cancer in patients who are medically fit and accepting of surgery. There are several non-cystectomy surgical options for patients motivated to pursue bladder sparing or are not medically fit for cystectomy. These include partial cystectomy, radical transurethral resection and radiation therapy with or without integration of cystectomy chemotherapy. Understanding the inclusion criteria and outcomes for these various non-cystectomy options is critical for optimizing cancer control and long-term preservation of quality of life.

Renal preservation using partial nephrectomy has gained acceptance over the past decade and now is the treatment of choice for small peripheral lesions (<4cm) and its role is expanding for lesions between 4 and 7 cm. However, the technical challenges and risks of partial nephrectomy may limit its adoption. Even though radical nephrectomy was once considered the standard of care, there is a need to understand the long-term tradeoffs of reduced renal function.

Novel systemic therapies for kidney cancer have filled a gap in our armamentarium to battle advanced disease. These targeted agents, however, come at considerable cost and have limited long-term benefits. Given the issues facing our delivery system, there is a need to understand the potential tradeoffs of widespread utilization of these agents.

Prostate cancer is the most common non-cutaneous cancer in men in the US, and the second leading cause of male cancer mortality. Intense research has focused on the low risk patient (who is likely being over treated) and the high-risk patient (who is likely being undertreated). However, the majority of patients treated today have intermediate risk disease. Patients and physicians continue to struggle with the optimal management of these patients. An understanding of the advantages and disadvantages of specific treatments allows optimal counseling of this patient population.

The management of patients with adverse pathology is also difficult. While randomized trials have demonstrated improved outcomes with adjuvant external beam radiation therapy, this modality has not been widely accepted. Many believe that close monitoring with early salvage therapy is as good as primary adjuvant radiation therapy. An understanding of the advantages and disadvantages of each approach is important to properly advise patients following treatment.

Germ cell tumors of the testicle are the most common solid tumor malignancies in young healthy men. For those with low stage disease, observation may become increasingly more attractive given that chemotherapy and radiation toxicities may be non-trivial in the long term. How best to achieve the necessary surveillance, and prevent the recurrences from being detected too late, is uncertain.

Educational Objectives (Afternoon)
Following participation in this program, attendees should be able to:
- Identify the quality gaps in the U.S health care system
- Describe strategies for improving the quality of urologic oncologic care
- Utilize the role of comparative effectiveness research in providing answers to clinical questions when trial data is lacking
- Identify better strategies for managing patients with bladder and prostate cancer
- Determine the tradeoffs of radical nephrectomy for local-regional disease and targeted therapies for advanced kidney cancer
- Report recent advances in systemic therapy for advanced prostate carcinoma
- Describe the tradeoffs of rigorous surveillance approaches to low stage tests cancer
- Utilize the value of health outcomes research for both identifying problem areas and implementing change

Accreditation: The American Urological Association Education & Research, Inc. (AU-AER) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association Education & Research, Inc. designates this live activity for a maximum of 8.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The combined SUO/SBUR morning session is designated for a maximum of 3.75 AMA PRA Category 1 Credits™.

The SUO afternoon session is designated for a maximum of 4.25 AMA PRA Category 1 Credits™.

The AU-AER takes responsibility for the content, quality, and scientific integrity of this CME activity.

AU-AER Disclosure Policy: As a provider accredited by the ACCME, the AU-AER must ensure balance, independence, objectivity and scientific rigor in all its activities.

All faculty participating in an educational activity provided by the AU-AER are required to disclose to the provider any relevant financial relationships with any commercial interest. The AU-AER must determine if the faculty’s relationships may influence the educational content with regard to exposition or conclusion and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent faculty with relevant financial relationships from serving as faculty, but rather to provide members of the audience with information on which they can make their own judgments.

Off-label or Unapproved Use of Drugs or Devices: It is the policy of the AU-AER to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer: The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AU-AER.

Evidence Based Content: As a provider of continuing medical education accredited by the ACCME, it is the policy of the AU-AER to review and certify that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

Special Assistance/Dietary Needs
The American Urological Association Education & Research, Inc. (AU-AER), an organization accredited for Continuing Medical Education (CME), complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, a written request should be submitted at least one month in advance. For additional assistance with your request please call (847) 264-5901.
Mark Your Calendar

12th Annual SUO Winter Meeting
to discuss current topics and strategies in Urologic Oncology
Wednesday, November 30 – Friday, December 2, 2011

YUO Dinner: Wednesday, November 30th
SUO Annual Banquet: Thursday, December 1st

Marriott Bethesda North Hotel &
Conference Center
5701 Marinelli Road
Bethesda, MD 20852
Phone: (301) 822-9200

The host hotel, the Marriott Bethesda North Hotel & Conference Center offering discounted room rates of $189.00 single/double occupancy, plus applicable tax when you mention you are with the SUO. Rooms book quickly so make your reservations early!

Visit our website at www.suonet.org for updates on the program agenda and meeting registration

CALL FOR ABSTRACTS: June 1, 2011
ABSTRACTS DEADLINE: September 1, 2011
Thank You to the
SUO 2010/2011
Industry Partners

DIAMOND LEVEL

AMGEN

Centocor Ortho Biotech Inc.

Dendreon
Targeting Cancer, Transforming Lives®

RUBY LEVEL

ENDO®
PHARMACEUTICALS

GE